References
- Lord CJ Ashworth A . The DNA damage response and cancer therapy. Nature481 (7381), 287 – 294 (2012).
- O'Connor MJ . Targeting the DNA damage response in cancer. Mol. Cell60 (4), 547 – 560 (2015).
- Brown JS O'Carrigan B Jackson SP Yap TA . Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov.7 (1), 20 – 37 (2017).
- Hengel SR Spies MA Spies M . Small-molecule inhibitors targeting DNA repair and DNA repair deficiency in research and cancer therapy. Cell Chem. Biol.24 (9), 1101 – 1119 (2017).
- Weterings E Gallegos AC Dominick LN et al. A novel small molecule inhibitor of the DNA repair protein Ku70/80. DNA Repair (Amst.)43, 98 – 106 (2016).
- Arora S Heyza J Zhang H et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget7 (46), 75104 – 75117 (2016).
- Exell JC Thompson MJ Finger LD et al. Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site. Nat. Chem. Biol.12 (10), 815 – 621 (2016).
- Pearl LH Schierz AC Ward SE Al-Lazikani B Pearl FMG . Therapeutic opportunities within the DNA damage response. Nat. Rev. Cancer15 (3), 166 – 180 (2015).
- Barkauskaite E Jankevicius G Ahel I . Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-Ribosylation. Mol. Cell58 (6), 935 – 946 (2015).
- Mortusewicz O Fouquerel E Amé J-C Leonhardt H Schreiber V . PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms. Nucleic Acids Res.39 (12), 5045 – 5056 (2011).
- Amé J-C Fouquerel E Gauthier LR et al. Radiation-induced mitotic catastrophe in PARG-deficient cells. J. Cell Sci.122 (Pt 12), 1990 – 2002 (2009).
- Koh DW Lawler AM Poitras MF et al. Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc. Natl Acad. Sci. USA101 (51), 17699 – 17704 (2004).
- Gravells P Grant E Smith KM James DI Bryant HE . Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. DNA Repair52, 81 – 91 (2017).
- James DI Smith KM Jordan AM et al. First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to olaparib. ACS Chem. Biol.11 (11), 3179 – 3190 (2016).
- Gravells P Neale J Grant E et al. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: a comparison with the PARP1/2/3 inhibitor olaparib. DNA Repair (Amst.)61, 25 – 36 (2018).
- Leenus Martin Tzuling Cheng Dominic I James et al. PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition. Presented at : AACR Annual Meeting 2018. Chicago, IL, USA, 2–6 October 2018 .
- Black S Kashkina E Kent T Pomerantz R . DNA polymerase θ: a unique multifunctional end-joining machine. Genes7 (9), 67 (2016).
- Mateos-Gomez PA Gong F Nair N Miller KM Lazzerini-Denchi E Sfeir A . Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature518 (7538), 254 – 257 (2015).
- Ceccaldi R Liu JC Amunugama R et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature518 (7538), 258 – 262 (2015).
- Higgins GS Harris AL Prevo R Helleday T McKenna WG Buffa FM . Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget1 (3), 175 – 184 (2010).
- Higgins GS Prevo R Lee YF et al. A small-interfering RNA screen of genes Involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res.70 (7), 2984 – 2993 (2010).
- Pomerantz RT . Development of polymerase theta inhibitors for precision medicine in BRCA-deficient cancers. Presented at : ACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Philadelphia, Penssylvania, USA, 26–30 October 2017 .